Skip to main content

Advertisement

Table 1 Patients characteristics

From: 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

Variables  
Number of patients (n) 43
Age (median [range]) 61 (35–78)
Gender (# male [%]) 19 (44.2%)
Stage (n [%]) IIIb: 4 (9.3%); IV: 39 (90.7%)
Demonstrable EGFR mutations (n [%]) 5 (11.6%)
Disease stabilization at 12 weeks (n [%]) 23 (53.5%)
Tumor shrinkage at 12 weeks (median [IQR]), in % of tumor size at baseline 15.8% (−2.5 to 26.2%)
Median overall survival (95% CI), in months 11.1 (10.1–17.9)
Median time-to-progression under BE (95% CI), in months 4.0 (2.8–6.0)
Median time-to-progression under CT (95% CI), in months 2.6 (1.7–5.7)
  1. The table summarizes the characteristics of the 43 patients included in the study